```
     FILE 'REGISTRY' ENTERED AT 17:02:21 ON 20 NOV 2008
L1                STRUCTURE UPLOADED
L2             50 S L1
L3           5058 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:03:34 ON 20 NOV 2008
L4            635 S L3/THU
L5          78047 S WRINKLE OR (FINE LINE) OR COSMETIC OR PHOTOAGING
L6             28 S L4 AND L5
L7             10 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'REGISTRY' ENTERED AT 17:54:11 ON 20 NOV 2008
L8                STRUCTURE UPLOADED
L9              2 S L8
L10               STRUCTURE UPLOADED
L11             1 S L10
L12            22 S L8 SSS FULL
L13            30 S L10 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:59:13 ON 20 NOV 2008
L14             2 S L12
L15            46 S L13
L16        364601 S SKIN OR TOPICAL OR COSMETIC
L17            11 S L15 AND L16
L18             8 S L17 AND (PY<2004 OR AY<2004 OR PRY<2004)
```

```
=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:02:21 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 NOV 2008  HIGHEST RN 1073427-79-8
DICTIONARY FILE UPDATES:  19 NOV 2008  HIGHEST RN 1073427-79-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10627994generic.str
```





chain nodes :
14 15 18 19 21 22 23 24 25 26 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13
chain bonds :
1-21 2-19 3-18 6-22 9-14 11-15 12-34 24-25 25-26
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13

exact/norm bonds :
1-21 2-19 3-18 6-22 7-11 8-13 9-14 11-12 11-15 12-13 12-34
exact bonds :
24-25 25-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10

G1:CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,H

G2:H,Ph,[*1],[*2]

```
Connectivity :
23:1 X maximum RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  18:CLASS  19:CLASS  21:CLASS
22:CLASS  23:CLASS  24:CLASS
25:CLASS  26:CLASS  34:CLASS
Generic attributes :
23:
Saturation              : Saturated

Element Count :
Node 23: Limited
    C,C1-8




L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 17:03:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1117 TO ITERATE

100.0% PROCESSED     1117 ITERATIONS                                 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         20335 TO    24345
PROJECTED ANSWERS:             4142 TO     6058

L2           50 SEA SSS SAM L1

=> d l2 scan

L2   50 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   4-Nonanone, 1-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)-2,2-
     dimethyl-
MF   C22 H30 N4 O
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Decanone, 10-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)-3-methyl-
MF C24 H34 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H22 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)-2,2-
    dimethyl-1-phenyl-
MF C24 H26 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss full
FULL SEARCH INITIATED 17:03:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 22227 TO ITERATE

100.0% PROCESSED 22227 ITERATIONS 5058 ANSWERS
SEARCH TIME: 00.00.04

L3 5058 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.82	179.03

FILE 'HCAPLUS' ENTERED AT 17:03:34 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 19 Nov 2008 (20081119/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l3/thu
           763 L3
       1070527 THU/RL
L4         635 L3/THU
                 (L3 (L) THU/RL)

=> s wrinkle or (fine line) or cosmetic or photoaging
          8727 WRINKLE
        345102 FINE
        773780 LINE
          1078 FINE LINE
                 (FINE(W)LINE)
         69383 COSMETIC
          1291 PHOTOAGING
L5        78047 WRINKLE OR (FINE LINE) OR COSMETIC OR PHOTOAGING

=> s l4 and l5
L6           28 L4 AND L5

=> s l6 and (PY<2004 or AY<2004 or PRY<2004)
      24012588 PY<2004
       4789993 AY<2004
       4261204 PRY<2004
L7           10 L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> d l7 1-10 ti abs bib

L7   ANSWER 1 OF 10  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
AB   The present invention relates to a foamable pharmaceutical carrier
     comprising a benefit agent, selected from the group consisting of a
     dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected
     from the group consisting of at least one surface-active agent; at least
     one polymeric agent and mixts. thereof; a solvent selected from the group
     consisting of water, a hydrophilic solvent, a hydrophobic solvent, a
     potent solvent, a polar solvent, a silicone, an emollient, and mixts.
     thereof, wherein the benefit agent, stabilizer and solvent are selected to
     provide a composition that is substantially resistant to aging and to phase
     separation and or can substantially stabilize other active ingredients.  The
     invention further relates to a foamable composition further containing a
liquefied
     hydrocarbon gas propellant.  Thus, a foaming vehicle composition comprised (i)
     an oil phase containing diisopropyl adipate (DISPA) 20.00, benzyl alc. 2.00,
     oleyl alc. 20.00, PPG 15 stearyl ether 2.00, sorbitan stearate 2.00, and
     stearyl alc. 3.00, and (ii) a water phase containing hydroxypropyl Me
     cellulose 0.15, xanthan gum 0.15, sucrose ester 3.00, propylene glycol
     17.70, and water 30.00%, resp.
AN   2008:226051  HCAPLUS <<LOGINID::20081120>>
DN   148:269446
TI   Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
IN   Tamarkin, Dov; Friedman, Doron; Berman, Tal; Ziv, Enbal; Schuz, David
PA   Foamix Ltd., Israel
SO   U.S. Pat. Appl. Publ., 37pp., Cont.-in-part of U.S. Ser. No. 717,897.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 30
     PATENT NO.          KIND    DATE        APPLICATION NO.          DATE
     ----------------    ----    --------    ----------------------   --------
PI   US 20080044444      A1      20080221    US 2007-825406           20070705 <--
     WO 2004037225       A2      20040506    WO 2003-IB5527           20031024 <--
```

```
     WO 2004037225        A3    20041229
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
              FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20050031547        A1    20050210    US 2004-835505          20040428 <--
     US 20050069566        A1    20050331    US 2004-911367          20040804 <--
     AU 2004313285         A1    20050929    AU 2004-313285          20041216 <--
     US 20050232869        A1    20051020    US 2005-78902           20050311 <--
     ZA 2005003298         A     20060830    ZA 2005-3298            20050425 <--
     US 20060140984        A1    20060629    US 2005-532618          20051222 <--
     AU 2006201878         A1    20070927    AU 2006-201878          20060504 <--
     US 20070280891        A1    20071206    US 2006-645444          20061226 <--
     US 20070292461        A1    20071220    US 2007-653205          20070112 <--
     US 20070253911        A1    20071101    US 2007-717897          20070313 <--
     WO 2008038147         A2    20080403    WO 2007-IB3759          20070705
     WO 2008038147         A3    20081016
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
              CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
              GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
              KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
              MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
              PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
              TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
          RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
              GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
              BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     US 20080050317        A1    20080228    US 2007-894668          20070820 <--
PRAI IL 2002-152486        A     20021025  <--
     US 2002-429546P       P     20021129  <--
     US 2003-492385P       P     20030804  <--
     WO 2003-IB5527        W     20031024  <--
     US 2003-530015P       P     20031216  <--
     US 2004-835505        A2    20040428
     US 2004-911367        A2    20040804
     US 2005-78902         A2    20050311
     US 2005-532618        A2    20051222
     US 2006-818634P       P     20060705
     US 2007-653205        A2    20070112
     US 2007-717897        A2    20070313
     US 2005-679020P       P     20050509
     US 2006-781868P       P     20060313
     US 2006-784793P       P     20060321
     US 2006-430599        A2    20060509
     US 2007-897638P       P     20070126
     US 2007-899176P       P     20070202

L7   ANSWER 2 OF 10  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Film forming foamable pharmaceutical and cosmetic compositions
     and cosmetic and therapeutic uses thereof
AB   The present invention provides a film-forming foamable cosmetic
     or pharmaceutical vehicle, and cosmetic and/or pharmaceutical
     compns. thereof.  Specifically, the foamable composition, includes (1) about 6%
```

to about 70% by weight of at least one organic carrier; (2) about 0.1% to about 5% by weight of at least one surface-active agent; (3) about 0.01% to about 5% by weight of at least one film forming agent; (4) water; and (5) about 3% to about 25% by weight of the total composition of at least one liquefied or compressed gas propellant. The composition is substantially alc. free and is used in treating, alleviating or preventing a disorder.

AN 2006:890398 HCAPLUS <<LOGINID::20081120>>

DN 145:298800

TI Film forming foamable pharmaceutical and cosmetic compositions and cosmetic and therapeutic uses thereof

IN Tamarkin, Dov; Friedman, Doron; Eini, Meir

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 20pp., Cont.-in-part of U.S. Ser. No. 922,358.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 30

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060193789	A1	20060831	US 2006-337747	20060123 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050069566	A1	20050331	US 2004-911367	20040804 <--
	US 20050074414	A1	20050407	US 2004-922358	20040820 <--
	ZA 2005003298	A	20060830	ZA 2005-3298	20050425 <--
	AU 2006201878	A1	20070927	AU 2006-201878	20060504 <--
PRAI	IL 2002-152486	A	20021025	<--	
	US 2002-429546P	P	20021129	<--	
	US 2003-492385P	P	20030804	<--	
	US 2003-497648P	P	20030825	<--	
	WO 2003-IB5527	A2	20031024	<--	
	US 2004-911367	A2	20040804		
	US 2004-922358	A2	20040820		

L7 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Topical treatment of dermatological disorders associated with reactive or dilated blood vessels

AB The invention provides a method of topically treating a dermatol. disorder. The method includes topically applying a therapeutically effective amount of a cosmetic or dermatol. composition to an affected area of the skin. The composition includes at least one compound that is (i) a polyhydroxy-aldonic acid, (ii) a polyhydroxy-aldonic lactone, (iii) a polyhydroxy-alduronic acid, (iv) a polyhydroxy-alduronic lactone, (v) a polyhydroxy-aldaric acid; (vi) a polyhydroxy-aldaric lactone, and (vii) an organic acid lactone having two or more hydroxyl or ketohydroxyl groups. The dermatol. disorder treated is one associated with reactive or dilated blood vessels. Also included in the invention are methods of treating dermatol. disorders associated with reactive blood vessels that include topical application of a therapeutically effective amount of a composition

AN 2004:934335 HCAPLUS <<LOGINID::20081120>>

DN 141:388761

TI Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040220259	A1	20041104	US 2004-817479	20040402 <--
	WO 2004093722	A2	20041104	WO 2004-US10454	20040405 <--
	WO 2004093722	A3	20050331		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-460322P P 20030404 <--
US 2004-817479 A 20040402
OS MARPAT 141:388761

L7 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Acidic drug complexes for improved bioavailability and delivery
AB Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition The compns. include a mol. complex formed between an acidic pharmaceutical drug and at least one functional substance. The compns. provide improved bioavailability and improved delivery of the drug into the cutaneous tissues. For example, methotrexate complex with L-lysine was found to have less skin irritation when applying topically to treat psoriasis on the forearm.
AN 2004:799452 HCAPLUS <<LOGINID::20081120>>
DN 141:301435
TI Acidic drug complexes for improved bioavailability and delivery
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004082628	A2	20040930	WO 2004-US8112	20040317 <--
	WO 2004082628	A3	20041119		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

```
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
            ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
            SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
            TD, TG
    US 20040220264       A1    20041104    US 2004-801134         20040316 <--
    AU 2004222305        A1    20040930    AU 2004-222305         20040317 <--
    CA 2519126           A1    20040930    CA 2004-2519126        20040317 <--
    EP 1603549           A2    20051214    EP 2004-757550         20040317 <--
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
PRAI US 2003-454631P     P     20030317    <--
    US 2004-801134       A     20040316
    WO 2004-US8112       A     20040317
OS  MARPAT 141:301435

L7  ANSWER 5 OF 10  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI  Non-amphoteric glutathione derivative compositions for topical application
AB  Topical compns. and methods including non-amphoteric derivs. of
    glutathione, for example, N-acyl-glutathiones, N-acyl-glutathione amides,
    and N-acyl-glutathione esters are disclosed for use in the treatment and
    prevention of cosmetic conditions and dermatol. disorders, are
    disclosed.  The non-amphoteric glutathione derivs. may have the structure
    of (I): R' -COCHNH (R2) H2CH2CONHCH(CH2SR3) CONHCH2 CO-R' wherein R' is
    independently selected from -OH, -NH2, -NHNH2, an alkoxyl group, an
    aralkoxyl group, and an aryloxyl group and R2 and R3 are each
    independently selected from a hydrogen atom or an acyl group, but if at
    least one R' is -OH, -NH2, or -NHNH2, then R2 is an acyl group.
AN  2004:100971  HCAPLUS <<LOGINID::20081120>>
DN  140:169245
TI  Non-amphoteric glutathione derivative compositions for topical application
IN  Yu, Ruey J.; Van Scott, Eugene J.
PA  USA
SO  PCT Int. Appl., 29 pp.
    CODEN: PIXXD2
DT  Patent
LA  English
FAN.CNT 1
    PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
    ---------------      ----   --------    -------------------    --------
PI  WO 2004010968        A1     20040205    WO 2003-US24048        20030731 <--
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
           CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
           GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
           LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
           PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
           TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    US 20040147452       A1     20040729    US 2003-626158         20030724 <--
    AU 2003257105        A1     20040216    AU 2003-257105         20030731 <--
PRAI US 2002-400252P     P      20020731    <--
    US 2003-626158       A      20030724    <--
    WO 2003-US24048      W      20030731    <--
RE.CNT  13    THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7  ANSWER 6 OF 10  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI  N-Acetyl cysteine and its topical use
```

AB Methods to alleviate or improve various cosmetic conditions and dermatol. disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors using compns. comprising N-acetyl-cysteine (isomeric or non-isomeric forms) and/or free acid, salt, lactone, amide or ester forms of N-acetyl-cysteine are described. The methods provided may also comprise application of a composition further containing various cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.
AN 2003:971738 HCAPLUS <<LOGINID::20081120>>
DN 140:23273
TI N-Acetyl cysteine and its topical use
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Pat. Appl. 2003 198,656.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030229141	A1	20031211	US 2003-462885	20030617 <--
	US 6159485	A	20001212	US 1999-227213	19990108 <--
	EP 1570840	A2	20050907	EP 2004-29094	20000107 <--
	EP 1570840	A3	20051116		
	R: DE, ES, FR, GB, IT				
	EP 1639994	A2	20060329	EP 2005-18302	20000107 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 6524593	B1	20030225	US 2000-560901	20000428 <--
	US 20030198656	A1	20031023	US 2003-371504	20030221 <--
	US 6808716	B2	20041026		
PRAI	US 1999-227213	A1	19990108	<--	
	US 2000-560901	A2	20000428	<--	
	US 2003-371504	A2	20030221	<--	
	EP 2000-902347	A3	20000107	<--	

L7 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Urea compositions for the treatment of skin disorders
AB The invention is directed to compns., methods of making the compns., and methods of treating cosmetic and dermatol. disorders with a composition that includes a mol. complex between urea and a functional substance that has at least one hydroxyl group and one carboxyl group either as a free acid, a salt, an amide or a lactone. The compns. are stable when compared to conventional urea-containing compns., and provide controlled-release of the urea. For example, urea 15 g was dissolved in 27 mL water and galacturonic acid 8 g was slowly added to form a mol. complex until the solution changed pH from 7.4 to 1.9. A clear solution containing the mol. complex was mixed with a hydrophilic ointment.
AN 2003:836770 HCAPLUS <<LOGINID::20081120>>
DN 139:341739
TI Urea compositions for the treatment of skin disorders
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086291	A2	20031023	WO 2003-US10823	20030409 <--
	WO 2003086291	A3	20040226		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2481702	A1	20031023	CA 2003-2481702	20030409 <--
	AU 2003220691	A1	20031027	AU 2003-220691	20030409 <--
	US 20040033963	A1	20040219	US 2003-409684	20030409 <--
	EP 1492486	A2	20050105	EP 2003-717012	20030409 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-371157P	P	20020410 <--		
	WO 2003-US10823	W	20030409 <--		

L7 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod
AB Background: Treatment of cutaneous leishmaniasis can be painful and protracted and cosmetic results are often unsatisfying. The immune modulator imiquimod has been reported to be suitable for the treatment of a variety of infectious skin diseases and neoplasias. Objective: We investigated the efficacy of topical application of imiquimod in the treatment of old world leishmaniasis in a placebo-controlled prospective study. Methods: Twelve patients were treated with imiquimod cream using a standard protocol, i.e. topical application three times a week, and a further three served as control group. Results: Lesions of cutaneous leishmaniasis regressed within the first 2-4 wk in 10 of the 12 patients, whereas in two patients no change was observed However, after 8 wk all lesions showed progression. Conclusion: Our results thus demonstrate that topical application of imiquimod alone is ineffective in treating old world cutaneous leishmaniasis. Further studies are required to demonstrate a possible benefit of imiquimod in combination with other, preferably orally administered medicines.
AN 2003:641685 HCAPLUS <<LOGINID::20081120>>
DN 139:239754
TI Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod
AU Seeberger, Josef; Daoud, Saleh; Pammer, Johannes
CS Department of Dermatology and Venereology, Faculty of Medicine, University of Damascus, Syria
SO International Journal of Dermatology (2003), 42(7), 576-579
CODEN: IJDEBB; ISSN: 0011-9059
PB Blackwell Publishing Ltd.
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Selective enzyme treatment of skin conditions

AB A method of treating skin conditions by providing compns. containing enzymes to selectively remove specific layers of skin. The depth of skin removed (i.e., vertical surface treated) is regulated by the type and concentration of enzyme or enzymes in the composition The surface area of skin removed (i.e., radial surface treated) is regulated by the area of topical application. Conditions treatable by the method include, but are not limited to, age-related conditions such as lines and wrinkles, infections, pigmentary disorders, follicular disorders such as acne, and hyperkeratotic disorders such as warts. The method and composition of the invention thus achieves the specificity and efficacy of more invasive methods such as surgery, while providing a composition that may be topically applied and is easy to use.
AN 2003:97805 HCAPLUS <<LOGINID::20081120>>
DN 138:147770
TI Selective enzyme treatment of skin conditions
IN Fein, Howard
PA USA
SO U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20030026794	A1	20030206	US 2001-919102	20010731 <--
PRAI US 2001-919102		20010731	<--	

L7 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use
AB Compns. comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatol. disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compns. comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects. A cream was prepared by mixing 50 g of 50% maltobionic acid with 50 g oil-in-water base, pH = 1.7. Efficacy of topical maltobionic acid in treatment of dry skin is reported.
AN 2001:31287 HCAPLUS <<LOGINID::20081120>>
DN 134:105670
TI Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001001932	A2	20010111	WO 2000-US16301	20000628 <--
WO 2001001932	A3	20010517		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

```
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6335023          B1    20020101    US 2000-487228          20000119 <--
     CA 2373852          A1    20010111    CA 2000-2373852         20000628 <--
     BR 2000011640       A     20020514    BR 2000-11640           20000628 <--
     EP 1227820          A2    20020807    EP 2000-950220          20000628 <--
     EP 1227820          B1    20060419
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
     JP 2003503436       T     20030128    JP 2001-507430          20000628 <--
     AU 775620           B2    20040805    AU 2000-63353           20000628 <--
     CN 1635864          A     20050706    CN 2000-809776          20000628 <--
     AT 323498           T     20060515    AT 2000-950220          20000628 <--
     EP 1685843          A1    20060802    EP 2006-6895            20000628 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI, CY
     PT 1227820          T     20060831    PT 2000-950220          20000628 <--
     ES 2262529          T3    20061201    ES 2000-950220          20000628 <--
     US 20020028227      A1    20020307    US 2001-987023          20011113 <--
     US 6740327          B2    20040525
     MX 2001PA13042      A     20030820    MX 2001-PA13042         20011217 <--
     HK 1048764          A1    20060915    HK 2003-100874          20030206 <--
     US 7452545          B2    20081118    US 2004-811998          20040330 <--
     US 20040180854      A1    20040916
     AU 2004212601       A1    20041014    AU 2004-212601          20040920 <--
     AU 2004212601       B2    20070614
     JP 2005232180       A     20050902    JP 2005-74658           20050316 <--
     US 20080090772      A1    20080417    US 2007-872459          20071015 <--
PRAI US 1999-141264P     P     19990630  <--
     US 2000-487228      A     20000119  <--
     AU 2000-63353       A     20000628  <--
     EP 2000-950220      A3    20000628  <--
     JP 2001-507430      A3    20000628  <--
     WO 2000-US16301     W     20000628  <--
     US 2001-987023      A1    20011113  <--
     US 2004-811998      A3    20040330
OS   MARPAT 134:105670


=> d his

     (FILE 'HOME' ENTERED AT 17:02:02 ON 20 NOV 2008)

     FILE 'REGISTRY' ENTERED AT 17:02:21 ON 20 NOV 2008
L1             STRUCTURE UPLOADED
L2           50 S L1
L3         5058 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:03:34 ON 20 NOV 2008
L4           635 S L3/THU
L5         78047 S WRINKLE OR (FINE LINE) OR COSMETIC OR PHOTOAGING
L6            28 S L4 AND L5
L7            10 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> log hold

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    34.48     213.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                 -8.00      -8.00

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:04:32 ON 20 NOV 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 17:53:54 ON 20 NOV 2008
FILE 'HCAPLUS' ENTERED AT 17:53:54 ON 20 NOV 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                 34.48     213.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                 -8.00      -8.00

=> file registry
COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                 34.48     213.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                 -8.00      -8.00

FILE 'REGISTRY' ENTERED AT 17:54:11 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 NOV 2008  HIGHEST RN 1073427-79-8
DICTIONARY FILE UPDATES:  19 NOV 2008  HIGHEST RN 1073427-79-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
```

experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10627994claim33.str



chain nodes :
14 15 16 17 19 20 21 22 24 25 33
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 26 27 28 29 30 31
chain bonds :
1-19 2-17 3-16 6-20 9-14 11-15 12-24 15-25 21-22 25-26 29-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13
26-27 26-31 27-28 28-29 29-30 30-31
exact/norm bonds :
7-11 8-13 9-14 11-12 12-13 26-27 26-31 27-28 28-29 29-30 29-33 30-31

exact bonds :
1-19 2-17 3-16 6-20 11-15 12-24 15-25 21-22 25-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10

G2:H,n-Bu,C(O)CH3,[*1]

G3:H,Cl,PhO,NH2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS
24:CLASS 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 33:CLASS

L8 STRUCTURE UPLOADED

=> s l8
SAMPLE SEARCH INITIATED 17:54:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 128 TO ITERATE

100.0% PROCESSED 128 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1882 TO 3238
PROJECTED ANSWERS: 2 TO 124

L9 2 SEA SSS SAM L8

=> d l9 scan

L9 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Ethanone, 1-[4-[2-(4-phenoxy-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-1-piperidinyl]-
MF C25 H26 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Imidazo[4,5-c]quinolin-4-amine, 1-[2-(4-piperidinyl)ethyl]-
MF C17 H21 N5
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>
Uploading C:\Program Files\STNEXP\Queries\10627994claim34.str





chain nodes :
14 15 16 18 19 20 27 29 30 31 32 33 34 35 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 21 22 23 24 25
chain bonds :
1-18 2-16 3-15 6-19 9-14 11-29 12-20 14-30 14-38 22-27 31-32 32-33 32-35
33-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13
21-22 21-25 22-23 23-24 24-25
exact/norm bonds :
7-11 8-13 9-14 11-12 12-13 12-20 14-38 21-22 21-25 22-23 23-24 24-25

exact bonds :
1-18 2-16 3-15 6-19 11-29 14-30 22-27 31-32 32-33 32-35 33-34
normalized bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10

```
G1:H,Ph,[*1]

G2:H,Ph,[*1],[*2]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  18:CLASS  19:CLASS
20:CLASS  21:Atom  22:Atom
23:Atom  24:Atom  25:Atom  27:CLASS  29:CLASS  30:CLASS  31:CLASS  32:CLASS
33:CLASS  34:CLASS
35:CLASS  38:CLASS



L10     STRUCTURE UPLOADED

=> s l10
SAMPLE SEARCH INITIATED 17:55:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1200 TO ITERATE

100.0% PROCESSED     1200 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        21922 TO    26078
PROJECTED ANSWERS:               1 TO       80

L11           1 SEA SSS SAM L10

=> log hols
'HOLS' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.92     214.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -8.00

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:55:38 ON 20 NOV 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 17:58:38 ON 20 NOV 2008
FILE 'REGISTRY' ENTERED AT 17:58:38 ON 20 NOV 2008
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.38	214.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

```
=> d his

     (FILE 'HOME' ENTERED AT 17:02:02 ON 20 NOV 2008)

     FILE 'REGISTRY' ENTERED AT 17:02:21 ON 20 NOV 2008
L1             STRUCTURE UPLOADED
L2              50 S L1
L3            5058 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 17:03:34 ON 20 NOV 2008
L4             635 S L3/THU
L5           78047 S WRINKLE OR (FINE LINE) OR COSMETIC OR PHOTOAGING
L6              28 S L4 AND L5
L7              10 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'REGISTRY' ENTERED AT 17:54:11 ON 20 NOV 2008
L8             STRUCTURE UPLOADED
L9               2 S L8
L10            STRUCTURE UPLOADED
L11              1 S L10

=> d l11 scan

L11  1 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   3H-Imidazo[4,5-c]quinolin-4-amine
MF   C10 H8 N4
CI   COM
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


ALL ANSWERS HAVE BEEN SCANNED


=> s l8 sss full
FULL SEARCH INITIATED 17:58:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      2416 TO ITERATE

100.0% PROCESSED     2416 ITERATIONS                          22 ANSWERS
SEARCH TIME: 00.00.01
```

```
L12          22 SEA SSS FUL L8

=> s l10 sss full
FULL SEARCH INITIATED 17:59:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     23862 TO ITERATE

100.0% PROCESSED    23862 ITERATIONS                                30 ANSWERS
SEARCH TIME: 00.00.02

L13          30 SEA SSS FUL L10

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   357.64     571.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -8.00

FILE 'HCAPLUS' ENTERED AT 17:59:13 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 20 Nov 2008  VOL 149 ISS 21
FILE LAST UPDATED: 19 Nov 2008  (20081119/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l12
L14           2 L12

=> s l13
L15          46 L13

=> d l14 1-2 ti abs bib

L14  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   1H-Imidazo[4,5-c]quinoline derivatives as novel potent TNF-α
     suppressors: synthesis and structure-activity relationship of 1-, 2-and
     4-substituted 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines
AB   Structural modification of imiquimod, which is known as an
```

interferon-α (IFN-α) inducer, for the aim of finding a novel and small-mol. tumor necrosis factor-α (TNF-α) suppressor and structure-activity relationship (SAR) are described. Structural modification of a imiquimod analog, 4-amino-1-2-(1-benzyl-4-piperidyl)ethyl-1H-imidazo[4,5-c]quinoline, which had moderate TNF-α suppressing activity without IFN-α inducing activity, led to a finding of 4-chloro-2-phenyl-1-[2-(4-piperidyl)ethyl]-1H-imidazo[4,5-c]quinoline with potent TNF-α suppressing activity. The relation between conformational direction of 2-(4-piperidyl)ethyl group at position 1 and TNF-α suppressing activity is also demonstrated by NMR.

AN 2003:393700 HCAPLUS <<LOGINID::20081120>>
DN 139:261235
TI 1H-Imidazo[4,5-c]quinoline derivatives as novel potent TNF-α suppressors: synthesis and structure-activity relationship of 1-, 2-and 4-substituted 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines
AU Izumi, Tomoyuki; Sakaguchi, Jun; Takeshita, Makoto; Tawara, Harumi; Kato, Ken-Ichi; Dose, Hitomi; Tsujino, Tomomi; Watanabe, Yoshinari; Kato, Hideo
CS R&D Headquarters, Research Division, Hokuriku Seiyaku Co., Ltd., 37-1-1, Inokuchi, Katsuyama, Fukui, 911-8555, Japan
SO Bioorganic & Medicinal Chemistry (2003), 11(12), 2541-2550
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 139:261235
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of imidazopyridine derivatives as TNF and IL-1 production inhibitors
GI



AB The title compds. I [A1 = (CH2)m; R1 is hydrogen, hydroxyl, alkyl, cycloalkyl, styryl or aryl; R2 is hydrogen, alkyl, halogeno, hydroxyl, amino, cyclic amino or phenoxy; ring A is an optionally substituted homocycle or heterocycle; R3 is a saturated nitrogenous heterocyclic group; and m is an integer of 0 to 3] are prepared In an in vitro test using cells, the title compound II.CF3CO2H at 0.001 μmol gave 79% inhibition of TNF-α production

AN 2000:133679 HCAPLUS <<LOGINID::20081120>>
DN 132:180573
TI Preparation of imidazopyridine derivatives as TNF and IL-1 production inhibitors

```
IN   Kato, Hideo; Sakaguchi, Jun; Aoyama, Makoto; Izumi, Tomoyuki; Kato,
     Ken-ichi
PA   Hokuriku Seiyaku Co., Ltd., Japan
SO   PCT Int. Appl., 111 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2000009506        A1    20000224    WO 1999-JP4381         19990812
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     JP 2000119271         A     20000425    JP 1999-216125         19990730
     TW 533209             B     20030521    TW 1999-88113701       19990811
     CA 2339562            A1    20000224    CA 1999-2339562        19990812
     AU 9951974            A     20000306    AU 1999-51974          19990812
     AU 744388             B2    20020221
     TR 200100439          T2    20010521    TR 2001-439            19990812
     EP 1104764            A1    20010606    EP 1999-937053         19990812
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     HU 2001003406         A2    20020228    HU 2001-3406           19990812
     HU 2001003406         A3    20021128
     BR 9914306            A     20020521    BR 1999-14306          19990812
     NZ 509939             A     20020828    NZ 1999-509939         19990812
     CZ 292544             B6    20031015    CZ 2001-503            19990812
     MX 2001PA01378        A     20020327    MX 2001-PA1378         20010206
     NO 2001000676         A     20010410    NO 2001-676            20010209
     IN 2001CN00217        A     20050304    IN 2001-CN217          20010214
     BG 105271             A     20011130    BG 2001-105271         20010219
     ZA 2001001452         A     20010917    ZA 2001-1452           20010221
     HR 2001000144         A1    20020430    HR 2001-144            20010228
     US 6518265            B1    20030211    US 2001-744959         20010502
PRAI JP 1998-241062        A     19980812
     JP 1999-216125        A     19990730
     WO 1999-JP4381        W     19990812
OS   MARPAT 132:180573
RE.CNT  17    THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s skin or topical or cosmetic
        290893 SKIN
         53553 TOPICAL
         69383 COSMETIC
L16     364601 SKIN OR TOPICAL OR COSMETIC

=> s l15 and l16
L17          11 L15 AND L16

=> s l17 and (PY<2004 or AY<2004 or PRY<2004)
      24012588 PY<2004
       4789993 AY<2004
       4261204 PRY<2004
```

```
L18          8 L17 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> d l18 1-8 ti abs bib

L18  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Imidazoquinoline adjuvants for vaccines
AB   The author discloses that topical administration of
     imidazoquinolines (e.g., imiquimod) enhances the T-cell response to
     genetic immunization.  In one example, the interferon-γ-producing
     CD8+ T-cell response to HBsAg was enhanced by the topical
     administration of Aldara.
AN   2006:388764  HCAPLUS <<LOGINID::20081120>>
DN   144:410797
TI   Imidazoquinoline adjuvants for vaccines
IN   Braun, Ralph Patrick
PA   Powdermed Limited, USA
SO   U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 102,615.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   US 20060088542      A1     20060427    US 2004-508143         20041118 <--
     US 20030185835      A1     20031002    US 2002-102615         20020319 <--
     WO 2003080114       A2     20031002    WO 2003-GB1203         20030319 <--
     WO 2003080114       A3     20031106
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2002-102615      B2     20020319  <--
     US 2002-366057P     P      20020319  <--
     WO 2003-GB1203      W      20030319  <--
OS   MARPAT 144:410797

L18  ANSWER 2 OF 8  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Adjuvant compositions and particle-delivered codon-optimized DNA vaccines
     encoding HIV antigens, useful in prophylaxis and treatment of HIV
     infections
AB   The present invention relates to certain adjuvant compns., and to vaccine
     and/or nucleic acid immunization strategies employing such compns.  The
     invention in particular relates to DNA vaccines that are useful in the
     prophylaxis and treatment of HIV infections, more particularly when
     administered by particle mediated delivery.  The examples disclose the use
     of imiquimod, in the form of Aldara cream, to enhance immune response to
     DNA vaccines encoding viral antigens, epitopes and fusions thereof.  Also
     disclosed is the optimization of the viral coding sequences to more
     closely resemble the codon usage of highly expressed human genes.  Methods
     used include gold particle-mediated immunization of plasmid DNA using
     "gene gun" DNA cartridges.
AN   2005:1261796  HCAPLUS <<LOGINID::20081120>>
DN   144:21828
TI   Adjuvant compositions and particle-delivered codon-optimized DNA vaccines
     encoding HIV antigens, useful in prophylaxis and treatment of HIV
```

infections
IN Braun, Ralph Patrick; Thomsen, Lindy; Van-Wely, Catherine; Ertl, Peter
PA Powdermed Limited, UK; Glaxo Group Limited
SO U.S. Pat. Appl. Publ., 75 pp., Cont.-in-part of U.S. Ser. No. 102,622.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050266024	A1	20051201	US 2005-507928	20050509 <--
	US 20030190308	A1	20031009	US 2002-102622	20020319 <--
	WO 2003080112	A2	20031002	WO 2003-GB1213	20030319 <--
	WO 2003080112	A3	20031106		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 20050256070	A1	20051117	US 2005-29465	20050106 <--
PRAI	US 2002-102622	A2	20020319	<--	
	US 2002-366058P	P	20020319	<--	
	WO 2003-GB1213	W	20030319	<--	

OS MARPAT 144:21828

L18 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Immunostimulatory combinations and treatments
AB The present invention provides immunostimulatory combinations and methods. Generally, the immunostimulatory combinations include a topical formulation of an immuno response modifier (IRM) compound and a pharmaceutical composition Generally, the methods include administering (a) a topical formulation of an IRM compound, and (b) a pharmaceutical composition to an administration site of a subject. A topical cream contained 2-propylthiazolo[4,5-c]quinolin-4-amine 1.00, isostearic acid 5.00, iso-Pr myristate 10.00, Poloxamer-188, 2.50, edetate disodium 0.05, Carbomer-974 1.50, propylene glycol 15.00, propylparaben 0.10, methylparaben 0.20, purified water 63.95, and 20% NaOH 0.70%.
AN 2005:177852 HCAPLUS <<LOGINID::20081120>>
DN 142:266767
TI Immunostimulatory combinations and treatments
IN Kedl, Ross M.; Tomai, Mark A.; Vasilakos, John P.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005018574	A2	20050303	WO 2004-US27712	20040825 <--
	WO 2005018574	A3	20060112		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

```
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
AU 2004266162          A1    20050303    AU 2004-266162          20040825 <--
CA 2551075             A1    20050303    CA 2004-2551075         20040825 <--
AU 2004268616          A1    20050310    AU 2004-268616          20040825 <--
CA 2536249             A1    20050310    CA 2004-2536249         20040825 <--
WO 2005020912          A2    20050310    WO 2004-US27633         20040825 <--
     W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
        CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
        GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
        LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
        NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
     RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
        AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
        EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
        SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
        SN, TD, TG
EP 1658035             A2    20060524    EP 2004-782185          20040825 <--
     R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
EP 1660122             A2    20060531    EP 2004-801917          20040825 <--
     R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
JP 2007503268          T     20070222    JP 2006-524827          20040825 <--
JP 2007504145          T     20070301    JP 2006-524843          20040825 <--
PRAI US 2003-497628P   P     20030825  <--
     US 2003-524213P   P     20031121  <--
     WO 2004-US27633   W     20040825
     WO 2004-US27712   W     20040825

L18  ANSWER 4 OF 8  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Compositions and methods for induction of opioid receptors, and
     therapeutic use
AB   The invention provides compns. and method for increasing expression of
     opioid receptors.  Generally, the compns. include an opioid
     receptor-inducing compound (e.g. an imidazoquinoline amine compound) and,
     optionally, an opioid receptor ligand.  Generally, the methods include
     contacting a cell with an amount of an opioid receptor-inducing compound
     effective for inducing expression of the opioid receptor and, optionally,
     contacting the cell with an opioid receptor ligand.  The methods of the
     invention may be used e.g. to reduce the effects of tissue damage.
AN   2004:905622  HCAPLUS <<LOGINID::20081120>>
DN   141:374755
TI   Compositions and methods for induction of opioid receptors, and
     therapeutic use
IN   Birmachu, Woubalem M. R.; Slade, Herbert B.; Stolpa, John C.; Urosevic,
     Mirjana
PA   3M Innovative Properties Company, USA
SO   U.S. Pat. Appl. Publ., 16 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ------------------  ----   --------    --------------------   --------
PI   US 20040214851      A1     20041028    US 2004-832737         20040427 <--
```

```
     WO 2004096144        A2    20041111    WO 2004-US12897        20040427 <--
     WO 2004096144        A3    20050909
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
     EP 1617845           A2    20060125    EP 2004-760404         20040427 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
PRAI US 2003-466227P      P     20030428  <--
     WO 2004-US12897      W     20040427

L18  ANSWER 5 OF 8  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Administration of dendritic cells partially matured in vitro for the
     treatment of tumors
AB   The disclosed invention provides populations of cells comprising partially
     matured dendritic cells that can be used for administration to individuals
     having a tumor.  Partially matured dendritic cells, contacted with a
     dendritic cell maturation agent (preferably Mycobacterium BCG and
     interferon γ) for about 1-10 h, or more, efficiently take up and
     process tumor antigens in the area of the tumor site, complete maturation,
     and can subsequently migrate to the lymph nodes of a treated individual.
     Once in the lymph node the now fully mature antigen-presenting dendritic
     cells secrete the appropriate cytokines (e.g., TNFα and IL-12) and
     contact T cells inducing a substantial anti-tumor immune response.  In a
     mouse model with xenografted human CT26 colon carcinoma partially matured
     dendritic cells had a considerable antitumor effect.  A patient diagnosed
     with a solid tumor was treated with chemotherapy, radiation therapy,
     cryotherapy, or brachytherapy and subsequently with partially matured
     dendritic cells administered intratumorally.  Following treatment, the
     tumor was resolved and the patient was protected from tumor recurrence.
AN   2004:515648  HCAPLUS <<LOGINID::20081120>>
DN   141:52876
TI   Administration of dendritic cells partially matured in vitro for the
     treatment of tumors
IN   Bosch, Marnix L.
PA   Northwest Biotherapeutics, Inc., USA
SO   PCT Int. Appl., 25 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    -------------------    --------
PI   WO 2004053072        A2     20040624    WO 2003-US38672        20031205 <--
     WO 2004053072        A3     20050616
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
            NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
            TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
```

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2509058	A1	20040624	CA 2003-2509058	20031205 <--
AU	2003293411	A1	20040630	AU 2003-293411	20031205 <--
EP	1567155	A2	20050831	EP 2003-790358	20031205 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR	2003017064	A	20051025	BR 2003-17064	20031205 <--
CN	1738619	A	20060222	CN 2003-80108975	20031205 <--
JP	2006510667	T	20060330	JP 2004-559310	20031205 <--
MX	2005PA06042	A	20050921	MX 2005-PA6042	20050606 <--
US	20060057120	A1	20060316	US 2005-538226	20050606 <--
IN	2005CN01136	A	20070824	IN 2005-CN1136	20050606 <--
PRAI US	2002-431267P	P	20021206 <--		
WO	2003-US38672	W	20031205 <--		

L18 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Immune adjuvant comprising imidazoquinoline amine or imidazopyridine amine for nucleic acid vaccine delivery

AB The invention relates to the fields of vaccines, vaccine adjuvants, mol. biol. and immunol., and generally relates to adjuvants and nucleic acid immunization techniques. More specifically, the invention relates to certain adjuvant compns., and to vaccine and/or nucleic acid immunization strategies employing such compns. The adjuvant compound is an imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- or oxazolo-quinolinamine or pyridinamines, imidazonaphthyridine or tetrahydroimidazonaphthyridine amine; especially imidazoquinoline, imiquimod or resiquimod. The vaccine is DNA vaccine comprising gene encoding HBsAg, HSV-2 antigen (e.g. gD or gB protein), cholera toxin or HSP70. The vaccine compns. are administered topically or transdermally in the forms of particles or creams.

AN 2003:777630 HCAPLUS <<LOGINID::20081120>>

DN 139:291106

TI Immune adjuvant comprising imidazoquinoline amine or imidazopyridine amine for nucleic acid vaccine delivery

IN Braun, Ralph Patrick

PA Powderject Research Limited, UK

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080114	A2	20031002	WO 2003-GB1203	20030319 <--
	WO 2003080114	A3	20031106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20030185835	A1	20031002	US 2002-102615	20020319 <--
	CA 2484049	A1	20031002	CA 2003-2484049	20030319 <--
	AU 2003216851	A1	20031008	AU 2003-216851	20030319 <--
	AU 2003216851	B2	20080417		

```
     EP 1487485          A2    20041222    EP 2003-712390          20030319 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005526793          T     20050908    JP 2003-577939          20030319 <--
     US 20060088542         A1    20060427    US 2004-508143          20041118 <--
PRAI US 2002-102615         A     20020319  <--
     US 2002-366057P        P     20020319  <--
     WO 2003-GB1203         W     20030319  <--
OS   MARPAT 139:291106

L18  ANSWER 7 OF 8  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Immune adjuvant comprising imidazoquinoline or imidazopyridine amines for
     DNA vaccines
AB   The invention relates to certain adjuvant compns., and to vaccine and/or
     nucleic acid immunization strategies employing such compns.  The invention
     in particular relates to DNA vaccines that are useful in the prophylaxis
     and treatment of HIV infections, more particularly when administered by
     particle mediated delivery.  The adjuvant uses imidazoquinoline amine,
     imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine,
     1,2-bridged imidazoquinoline amine, thiazolo- and oxazoloquinolinamine or
     pyridinamine, imidazonaphthyridine or tetrahydronaphthyridine amine to
     enhance immune response.
AN   2003:777628  HCAPLUS <<LOGINID::20081120>>
DN   139:291105
TI   Immune adjuvant comprising imidazoquinoline or imidazopyridine amines for
     DNA vaccines
IN   Braun, Ralph Patrick; Thomsen, Lindy; Van-Wely, Catherine; Ertl, Peter
PA   Powderject Research Limited, UK; Glaxo Group Limited
SO   PCT Int. Appl., 137 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2003080112       A2     20031002    WO 2003-GB1213          20030319 <--
     WO 2003080112       A3     20031106
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20030190308         A1     20031009    US 2002-102622          20020319 <--
     CA 2484044             A1     20031002    CA 2003-2484044         20030319 <--
     AU 2003216852          A1     20031008    AU 2003-216852          20030319 <--
     AU 2003216852          B2     20080911
     EP 1487486             A2     20041222    EP 2003-712391          20030319 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005533752          T     20051110    JP 2003-577938          20030319 <--
     US 20050256070         A1    20051117    US 2005-29465           20050106 <--
     US 20050266024         A1    20051201    US 2005-507928          20050509 <--
PRAI US 2002-102622         A     20020319  <--
     US 2002-366058P        P     20020319  <--
     WO 2003-GB1213         W     20030319  <--
OS   MARPAT 139:291105
```

L18 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Use of imidazoquinolinamines as adjuvants in DNA vaccination
AB The present invention relates to the use of a 1H-imidazo[4,5-c]quinolin-4-amine derivative as an adjuvant for use with nucleic acid vaccination. The vaccine comprises the adjuvant and a nucleotide sequence encoding an antigen associated with a disease. The diseases can include infection, cancer, allergy, and autoimmunity.
AN 2002:240588 HCAPLUS <<LOGINID::20081120>>
DN 136:261816
TI Use of imidazoquinolinamines as adjuvants in DNA vaccination
IN Thomsen, Lindy Louise; Tite, John Philip; Topley, Peter
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002024225	A1	20020328	WO 2001-GB4207	20010920	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	CA 2422863	A1	20020328	CA 2001-2422863	20010920	<--
	AU 2001087908	A	20020402	AU 2001-87908	20010920	<--
	EP 1318835	A1	20030618	EP 2001-967535	20010920	<--
	EP 1318835	B1	20080716			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	BR 2001013982	A	20030819	BR 2001-13982	20010920	<--
	HU 2003001180	A2	20040301	HU 2003-1180	20010920	<--
	HU 2003001180	A3	20051128			
	JP 2004509150	T	20040325	JP 2002-528295	20010920	<--
	NZ 524792	A	20040924	NZ 2001-524792	20010920	<--
	CN 1197620	C	20050420	CN 2001-818617	20010920	<--
	AU 2001287908	B2	20050630	AU 2001-287908	20010920	<--
	TW 287453	B	20071001	TW 2001-90123505	20010920	<--
	AT 401097	T	20080815	AT 2001-967535	20010920	<--
	CA 2461056	A1	20030327	CA 2002-2461056	20020918	<--
	WO 2003025003	A2	20030327	WO 2002-EP10592	20020918	<--
	WO 2003025003	A3	20031204			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	AU 2002362368	A1	20030401	AU 2002-362368	20020918	<--
	AU 2002362368	B2	20060921			
	EP 1427826	A2	20040616	EP 2002-798748	20020918	<--

```
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     BR 2002012619        A     20040817    BR 2002-12619          20020918 <--
     HU 2004002259        A2    20050128    HU 2004-2259           20020918 <--
     CN 1606624           A     20050413    CN 2002-823087         20020918 <--
     CN 100392085         C     20080604
     JP 2005511019        T     20050428    JP 2003-528849         20020918 <--
     NZ 531814            A     20051028    NZ 2002-531814         20020918 <--
     CN 101255434         A     20080903    CN 2008-10090890       20020918 <--
     NO 2003001274        A     20030519    NO 2003-1274           20030319 <--
     MX 2003PA02453       A     20030619    MX 2003-PA2453         20030319 <--
     ZA 2003002231        A     20040505    ZA 2003-2231           20030320 <--
     IN 2003DN00419       A     20070302    IN 2003-DN419          20030320 <--
     US 20040076633       A1    20040422    US 2003-380981         20030923 <--
     ZA 2004002189        A     20050429    ZA 2004-2189           20040318 <--
     NO 2004001157        A     20040519    NO 2004-1157           20040319 <--
     MX 2004PA02631       A     20040708    MX 2004-PA2631         20040319 <--
     IN 2004KN00369       A     20060217    IN 2004-KN369          20040319 <--
     US 20070015721       A1    20070118    US 2004-490011         20041025 <--
     IN 2007KN02170       A     20080801    IN 2007-KN2170         20070613 <--
     US 20070248614       A1    20071025    US 2007-764814         20070619 <--
PRAI GB 2000-23008        A     20000920  <--
     WO 2001-GB4207       W     20010920  <--
     GB 2001-29604        A     20011211  <--
     GB 2002-6462         A     20020319  <--
     CN 2002-823087       A3    20020918  <--
     WO 2002-EP10592      W     20020918  <--
     US 2003-380981       A1    20030923  <--
     IN 2004-KN369        A3    20040319
OS   MARPAT 136:261816
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```